<DOC>
	<DOC>NCT00397358</DOC>
	<brief_summary>This is a Phase IV study evaluating triglyceride levels in peritoneal dialysis patients.</brief_summary>
	<brief_title>Effect of Extraneal (Icodextrin)on Triglyceride Levels in PD Patients</brief_title>
	<detailed_description>This prospective, open label, multi-center study evaluates the use of 7.5% icodextrin used in the long-dwell exchange in peritoneal dialysis patients with elevated triglyceride levels. Fasting triglyceride levels will be measured during the study.</detailed_description>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Icodextrin</mesh_term>
	<mesh_term>Dialysis Solutions</mesh_term>
	<criteria>written informed consent CAPD/APD on dialysis for at least 3 months Elevated fasting triglyceride levels enrolled in another study requiring IRB approval allergy to starchbased polymers glycogen storage disease maltose or isomaltose intolerance active alcohol/substance abuse Pregnant or nursing received an investigational drug within 30 days of screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Peritoneal Dialysis</keyword>
	<keyword>Hypertriglyceridemia</keyword>
	<keyword>Extraneal(7.5% icodextrin)Peritoneal Dialysis Solution</keyword>
</DOC>